Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on June 12, 2007
JNCI Journal of the National Cancer Institute 2007 99(12):913-914; doi:10.1093/jnci/djm032
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/12/913    most recent
djm032v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Savage, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Savage, L.
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

NEWS

Researchers Wonder Why High-Risk Women Are Not Taking Chemoprevention Drugs

Liz Savage

The first 10% of the full text of this article appears below.

Many women at high risk for breast cancer could be taking a powerful anticancer drug to slash their risk in half. Yet only a minority takes the drug.

Cancer prevention experts still aren't sure why. Are they abstaining because they believe the odds against breast cancer are in their favor? Are they unwilling to commit to a daily pill for a disease they don't yet have? Do they feel the harms outweigh the benefits? Or are their doctors reluctant to prescribe the drug?

As is often the case, it's probably a bit of all four.

No one knows the exact number of women taking tamoxifen to prevent breast cancer, currently the only breast cancer prevention drug with U.S. Food and Drug Administration approval. A few studies have attempted to quantify women's . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

NCI Director Opts Against Breast Cancer Prevention Trial In Favor of Biomarkers
Liz Savage
J Natl Cancer Inst 2007 99: 1282-1289. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 JCOHome page
K. Visvanathan, R. T. Chlebowski, P. Hurley, N. F. Col, M. Ropka, D. Collyar, M. Morrow, C. Runowicz, K. I. Pritchard, K. Hagerty, et al.
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction
J. Clin. Oncol., July 1, 2009; 27(19): 3235 - 3258.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. T. Chlebowski, G. L. Anderson, D. S. Lane, A. K. Aragaki, T. Rohan, S. Yasmeen, G. Sarto, C. A. Rosenberg, F. A. Hubbell, and For the Women's Health Initiative Investigators
Predicting Risk of Breast Cancer in Postmenopausal Women by Hormone Receptor Status
J Natl Cancer Inst, November 21, 2007; 99(22): 1695 - 1705.
[Abstract] [Full Text] [PDF]